Renaissance Technologies LLC trimmed its position in shares of Affimed NV (NASDAQ:AFMD) by 66.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59,497 shares of the biopharmaceutical company’s stock after selling 118,013 shares during the period. Renaissance Technologies LLC owned approximately 0.10% of Affimed worth $259,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. CIBC World Markets Inc. purchased a new stake in shares of Affimed during the 3rd quarter worth approximately $104,000. EAM Investors LLC purchased a new stake in shares of Affimed during the 3rd quarter worth approximately $656,000. Prescott Group Capital Management L.L.C. purchased a new stake in shares of Affimed during the 3rd quarter worth approximately $714,000. EAM Global Investors LLC purchased a new stake in shares of Affimed during the 3rd quarter worth approximately $2,064,000. Finally, FMR LLC purchased a new stake in shares of Affimed during the 3rd quarter worth approximately $5,552,000. 42.36% of the stock is currently owned by institutional investors and hedge funds.

Several analysts have recently issued reports on AFMD shares. ValuEngine raised Affimed from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. BidaskClub raised Affimed from a “sell” rating to a “hold” rating in a report on Tuesday, November 20th. Finally, Zacks Investment Research raised Affimed from a “sell” rating to a “hold” rating in a report on Thursday, January 3rd. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $4.81.

NASDAQ:AFMD opened at $3.32 on Monday. The firm has a market cap of $207.14 million, a P/E ratio of -4.26 and a beta of 3.42. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 3.66. Affimed NV has a fifty-two week low of $1.40 and a fifty-two week high of $7.35.

COPYRIGHT VIOLATION WARNING: This news story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2019/02/11/renaissance-technologies-llc-sells-118013-shares-of-affimed-nv-afmd.html.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.

Further Reading: What is the NASDAQ Stock Market?

Want to see what other hedge funds are holding AFMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Affimed NV (NASDAQ:AFMD).

Institutional Ownership by Quarter for Affimed (NASDAQ:AFMD)

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.